Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that ...

EDT Neurogene (NGNE) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on ...

Neurogene Inc. (NASDAQ:NGNE) is an important biotech to watch during this year, and it is because it is gearing up for two key catalysts that investors need to keep an eye on. The first of which ...

2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares. Last week, the company reported that NGN-401 had shown ...

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and ...

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing its ...

Investing.com — Dans un environnement de marché turbulent, l’action NGNE a atteint son plus bas niveau sur 52 semaines, se négociant à 8,35$, bien en dessous de son pic de 74,49$. Ce niveau de prix re ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter ...